Loading
Cancer Treatment and Pharmacology / Complementary and Alternative Medicine Studies · Journal article
Supportive Care in Cancer · September 10, 2026
Points the other way from the current standard, or from comparable studies.
This phase III RCT reports that adjunctive homeopathy was associated with higher quality of life and longer median survival than placebo in stage IV NSCLC patients over 730 days. However, the original publication was retracted by the journal in November 2025 after corrections, with majority co-author disagreement, creating substantial uncertainty about the validity and interpretability of these results despite the sound trial design.
Prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter phase III trial. Patients with stage IV non-small cell lung cancer receiving conventional anticancer treatment.. Intervention: Individualized homeopathic medicinal products (HMPs) of plant, mineral, or animal origin, added to conventional anticancer therapy.. Compared with: Placebo in double-blinded randomized arm; non-randomized conventional treatment control group.. n = 98. Multicenter; specific countries and number of centers not stated..
Median survival: 435 days (homeopathy) vs 257 days (placebo) vs 228 days (control); p = 0.010 (homeopathy vs placebo) 2-year survival rates: 45.1% (homeopathy) vs 23.4% (placebo) vs 13.5% (control); p = 0.020 (homeopathy vs placebo) Global health status (QoL) higher in homeopathy group than placebo at 9 weeks and 18 weeks (p < 0.001)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Although the trial design is rigorous and reports substantial benefits for adjunctive homeopathy in survival and quality of life, the November 2025 retraction of the original publication with majority co-author disagreement fundamentally undermines confidence in these findings. Clinicians should not base treatment decisions on these results pending independent replication and resolution of the circumstances surrounding the retraction.
A phase III RCT with adequate design and sample size reporting survival and QoL benefits for homeopathy, but the original publication was retracted by the journal in November 2025 after corrections, with majority co-author disagreement, creating fundamental uncertainty about the reliability and interpretation of these findings.
As stated by the source record.
Quoted from the source exactly as published.
Although the trial design is rigorous and reports substantial benefits for adjunctive homeopathy in survival and quality of life, the November 2025 retraction of the original publication with majority co-author disagreement fundamentally undermines confidence in these findings. Clinicians should not base treatment decisions on these results pending independent replication and resolution of the circumstances surrounding the retraction.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Alongside conventional anticancer treatment, add-on homeopathy might help to alleviate adverse effects of conventional therapy. The aim of this study was to replicate previous studies on the effect of adjunctive homeopathy on quality of life (QoL) and survival in non-small cell lung cancer (NSCLC) patients. In this prospective, randomized, placebo-controlled, double-blind, three-arm multicenter phase III study with quadruple-checked data analysis, we investigated the potential effects of an add-on homeopathic treatment compared to placebo in patients with stage IV NSCLC in terms of QoL. Ninety-eight received either individualized homeopathic medicinal products (HMPs; n = 51) or placebo ( n = 47) in a double-blinded fashion. Fifty-two control patients without homeopathic treatment were only observed in terms of their survival rate. The ingredients of the various HMPs were mainly prepared of plant, mineral, or animal origin. The data entry and statistical analysis were subject to an exceptional quadruple-checked data analysis process. The analysis presented in this article was inspired by our earlier report of this trial published in The Oncologist in 2020, which was retracted by that journal in November 2025 after two corrections; a majority of the co-authors disagreed with this decision. The present article is based on the same trial dataset but was deliberately designed to highlight the unique research methodology: design and preparation by a lead statistician, data entry, data clearing and independent statistical evaluation were performed in four mutually independent steps, reporting follows the CONSORT statement, and the interpretation of the findings has been reframed conservatively. Global health status (QoL) was higher in the homeopathy group than in the placebo group after 9 weeks and after 18 weeks ( p < 0.001). With the exception of cognitive functioning at 9 weeks and of pain, diarrhea and financial difficulties at 9 weeks, all functional and symptom scales of the EORTC QLQ-C30 favored the homeopathy group ( p < 0.001 for the multivariate comparisons), with between-group differences exceeding the threshold of 10 points that is generally regarded as clinically meaningful. Median survival time over the 730-day observation period was 435 days in the homeopathy group, 257 days in the placebo group ( p = 0.010), and 228 days in the non-randomized control group ( p < 0.001); the corresponding 2-year survival rates were 45.1%, 23.4%, and 13.5% (homeopathy vs. placebo p = 0.020; homeopathy vs. control p < 0.001). The difference between the placebo group and the non-randomized control group was not statistically significant ( p = 0.154). In this trial, add-on homeopathy was associated with better quality of life across most functional and symptom domains, with clinically meaningful effect sizes congruently to a previous open study. Survival time was significantly longer in the homeopathy group compared to both the placebo and control groups. Independent replication, ideally within contemporary immuno-oncological treatment regimens is required. ClinicalTrials.gov; No.: NCT01509612; January 7, 2012
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.